{"schema_version":"secwatch.filing_event.v1","accession":"0001116463-25-000008","form_type":"8-K/A","ticker":"OSUR","cik":"0001116463","company_name":"ORASURE TECHNOLOGIES INC","filed_at":"2025-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.965836+00:00","generated_at":"2026-05-25T02:58:46.159150+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition","bullets":["Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.","Accumulated deficit reached $149.7M as of Sep 30, 2024; total liabilities $55.3M exceed assets $31.1M.","Cash and cash equivalents $3.8M at Sep 30, 2024; convertible notes of $27.9M outstanding.","Revenue from grants only $1.1M in 9 months 2024, $0.9M in FY2023; no product revenue.","Going concern uncertainty noted, but expected to be resolved by OraSure acquisition in Dec 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001116463-25-000008","json":"https://secwatch.observer/filing/0001116463-25-000008.json","markdown":"https://secwatch.observer/filing/0001116463-25-000008.md","text":"https://secwatch.observer/filing/0001116463-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1116463/000111646325000008/0001116463-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1116463/000111646325000008/osur-20241219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T02:58:46.159150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}